Compare ENVX & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENVX | NGNE |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | United States | United States |
| Employees | 664 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 741.7M | 744.9M |
| IPO Year | 2020 | 2014 |
| Metric | ENVX | NGNE |
|---|---|---|
| Price | $3.35 | $37.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $13.61 | ★ $63.57 |
| AVG Volume (30 Days) | ★ 8.2M | 188.6K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.94 | 0.93 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $31,821,000.00 | N/A |
| Revenue This Year | $30.37 | N/A |
| Revenue Next Year | $238.73 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 37.91 | N/A |
| 52 Week Low | $3.06 | $15.93 |
| 52 Week High | $14.21 | $43.66 |
| Indicator | ENVX | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 37.80 | 53.13 |
| Support Level | $3.06 | $18.24 |
| Resistance Level | $5.04 | $42.84 |
| Average True Range (ATR) | 0.28 | 2.46 |
| MACD | 0.02 | -0.16 |
| Stochastic Oscillator | 14.91 | 42.88 |
Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, the United States, Norway, Taiwan, and other regions.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.